文献速递自身免疫性与大疱性皮肤病

多西环素与泼尼松龙治疗大疱性类天疱疮的成本效果分析:BLISTER试验

Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial.
PubMed 文献 · Br J Dermatol · 2018-01-15

基于BLISTER随机对照试验,从卫生服务角度比较多西环素与泼尼松龙初始治疗大疱性类天疱疮的成本效果。1年时两组成本和QALYs无稳健差异,但按基线水疱严重程度分层后,严重水疱(>30个)患者使用多西环素净成本更高且生活质量更差,泼尼松龙可能更具成本效果。

要点

  • 轻度至中度水疱患者,多西环素与泼尼松龙的成本效果无明确优劣。
  • 严重水疱(>30个)患者,泼尼松龙初始治疗可能更具成本效果。
  • 临床决策应结合药物安全性、有效性及患者偏好。

核心结论

  • 轻度至中度水疱患者应基于药物安全性、有效性和患者偏好选择治疗,两种策略对NHS资源使用无明确优劣。
  • 严重水疱患者起始泼尼松龙治疗可能更具成本效果。

研究设计与样本

  • 基于BLISTER试验的多中心、平行组、研究者盲法随机对照试验,收集EuroQoL-5D-3L生活质量数据和资源使用数据。
  • 采用双变量回归分析成本和QALYs,对缺失数据进行多重插补,从卫生服务角度进行增量成本效果的概率评估。

主要发现

  • 轻度或中度水疱(≤30个)患者,两组净成本和结局相似。

关键数值与推荐

  • 严重水疱定义为基线水疱数量>30个。

临床怎么用

  • 临床医生在为轻度至中度水疱患者选择初始治疗时,应综合考虑药物安全性、有效性和患者偏好。
  • 对于严重水疱患者,泼尼松龙初始治疗可能更符合成本效果原则。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder associated with significant morbidity and mortality. Doxycycline and prednisolone to treat bullous pemphigoid were compared within a randomized controlled trial (RCT). OBJECTIVES: To compare the cost-effectiveness of doxycycline-initiated and prednisolone-initiated treatment for patients with BP. METHODS: Quality-of-life (EuroQoL-5D-3L) and resource data were collected as part of the BLISTER trial: a multicentre, parallel-group, investigator-blinded RCT. Within-trial analysis was performed using bivariate regression of costs and quality-adjusted life-years (QALYs), with multiple imputation of missing data, informing a probabilistic assessment of incremental treatment cost-effectiveness from a health service perspective. RESULTS: In the base case, there was no robust difference in costs or QALYs per patient at 1 year comparing doxycycline- with prednisolone-initiated therapy [net cost £959, 95% confidence interval (CI) -£24 to £1941; net QALYs -0·024, 95% CI -0·088 to 0·041]. However, the findings varied by baseline blister severity. For patients with mild or moderate blistering (≤ 30 blisters) net costs and outcomes were similar. For patients with severe blistering (> 30 blisters) net costs were higher (£2558, 95% CI -£82 to £5198) and quality of life poorer (-0·090 QALYs, 95% CI -0·22 to 0·042) for patients starting on doxycycline. The probability that doxycycline would be cost-effective for those with severe pemphigoid was 1·5% at a willingness to pay of £20 000 per QALY. CONCLUSIONS: Consistently with the clinical findings of the BLISTER trial, patients with mild or moderate blistering should receive treatment guided by the safety and effectiveness of the drugs and patient preference - neither strategy is clearly a preferred use of National Health Service resources. However, prednisolone-initiated treatment may be more cost-effective for patients with severe blistering.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Mason JM, Chalmers JR, Godec T, et al. Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial. Br J Dermatol. 2018. PMID: 28940316. doi:10.1111/bjd.16006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。